Abraxis BioScience
E932802
Abraxis BioScience was a biopharmaceutical company best known for developing the cancer drug Abraxane and focusing on nanoparticle-based chemotherapy treatments.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Abraxis BioScience canonical | 3 |
How this entity was disambiguated
This entity first appeared as the object of triple T11553575 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Abraxis BioScience Context triple: [Patrick Soon-Shiong, founded, Abraxis BioScience]
-
A.
Array BioPharma
Array BioPharma is a biopharmaceutical company known for developing targeted small-molecule cancer therapies, particularly in oncology and rare diseases.
-
B.
Innogen
Innogen is the original name of Imogen, the virtuous and wronged heroine of William Shakespeare’s play "Cymbeline."
-
C.
Nautilus Biotechnology
Nautilus Biotechnology is a life sciences company developing next-generation, high-throughput proteomics platforms to enable comprehensive analysis of the human proteome for research and drug discovery.
-
D.
Ridgeback Biotherapeutics
Ridgeback Biotherapeutics is a biotechnology company focused on developing antiviral and immunotherapy treatments for serious infectious diseases, including Ebola and COVID-19.
-
E.
Portola Pharmaceuticals
Portola Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for thrombosis and other hematologic conditions.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Abraxis BioScience Target entity description: Abraxis BioScience was a biopharmaceutical company best known for developing the cancer drug Abraxane and focusing on nanoparticle-based chemotherapy treatments.
-
A.
Array BioPharma
Array BioPharma is a biopharmaceutical company known for developing targeted small-molecule cancer therapies, particularly in oncology and rare diseases.
-
B.
Innogen
Innogen is the original name of Imogen, the virtuous and wronged heroine of William Shakespeare’s play "Cymbeline."
-
C.
Nautilus Biotechnology
Nautilus Biotechnology is a life sciences company developing next-generation, high-throughput proteomics platforms to enable comprehensive analysis of the human proteome for research and drug discovery.
-
D.
Ridgeback Biotherapeutics
Ridgeback Biotherapeutics is a biotechnology company focused on developing antiviral and immunotherapy treatments for serious infectious diseases, including Ebola and COVID-19.
-
E.
Portola Pharmaceuticals
Portola Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for thrombosis and other hematologic conditions.
- F. None of above. chosen
Statements (38)
| Predicate | Object |
|---|---|
| instanceOf | biopharmaceutical company ⓘ |
| abbreviation | formerly traded as ABII on NASDAQ ⓘ |
| acquiredBy | Celgene ⓘ |
| acquisitionDate | 2010 ⓘ |
| acquisitionValue | approximately 2.9 billion US dollars ⓘ |
| country |
United States
ⓘ
linked to:
United States of America
|
| developedFor |
treatment of metastatic breast cancer
ⓘ
treatment of non-small cell lung cancer ⓘ treatment of pancreatic cancer ⓘ |
| developedTechnology | nab-paclitaxel formulation ⓘ |
| dissolved | 2010 ⓘ |
| focus | nanoparticle-based chemotherapy ⓘ |
| foundedBy | Patrick Soon-Shiong ⓘ |
| headquartersLocation | Los Angeles, California ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| keyPerson | Patrick Soon-Shiong ⓘ |
| knownFor |
development of Abraxane
ⓘ
nanoparticle albumin-bound (nab) technology ⓘ |
| marketedBrand | Abraxane ⓘ |
| notableDrug | Abraxane ⓘ |
| parentCompanyAfterAcquisition | Celgene ⓘ |
| predecessor |
American BioScience
ⓘ
American Pharmaceutical Partners ⓘ |
| productDeveloped | Abraxane ⓘ |
| regulatoryApproval |
U.S. FDA approval for Abraxane in metastatic breast cancer
ⓘ
U.S. FDA approval for Abraxane in non-small cell lung cancer ⓘ U.S. FDA approval for Abraxane in pancreatic cancer ⓘ |
| researchArea |
nanoparticle therapeutics
ⓘ
targeted drug delivery ⓘ |
| specialization |
nanomedicine
ⓘ
oncology therapeutics ⓘ |
| status | defunct ⓘ |
| successor | Celgene ⓘ |
| technologyBasis | albumin-bound nanoparticle delivery ⓘ |
| therapeuticArea |
cancer
ⓘ
oncology ⓘ |
| tradedAs | NASDAQ:ABII ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Abraxis BioScience Description of subject: Abraxis BioScience was a biopharmaceutical company best known for developing the cancer drug Abraxane and focusing on nanoparticle-based chemotherapy treatments.
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.